142 related articles for article (PubMed ID: 2447445)
21. Acute vascular rejection involving the major coronary arteries of a cardiac allograft.
Yowell RL; Hammond EH; Bristow MR; Watson FS; Renlund DG; O'Connell JB
J Heart Transplant; 1988; 7(3):191-7. PubMed ID: 3290402
[TBL] [Abstract][Full Text] [Related]
22. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients.
Meng HL; Jin XB; Li XT; Wang HW; Lü JJ
Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748
[TBL] [Abstract][Full Text] [Related]
23. Antibody and complement in transplant vasculopathy.
Wehner J; Morrell CN; Reynolds T; Rodriguez ER; Baldwin WM
Circ Res; 2007 Feb; 100(2):191-203. PubMed ID: 17272820
[TBL] [Abstract][Full Text] [Related]
24. Complement mediates attenuation of endothelium-dependent relaxations in canine coronary arteries after porcine serum exposure: a mechanism for vascular thrombosis in xenograft hyperacute rejection.
Cable DG; Hisamochi K; Schaff HV
Circulation; 1997 Nov; 96(9 Suppl):II-58-63; discussion II-63-4. PubMed ID: 9386076
[TBL] [Abstract][Full Text] [Related]
25. Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications.
Hammond EH; Yowell RL; Nunoda S; Menlove RL; Renlund DG; Bristow MR; Gay WA; Jones KW; O'Connell JB
J Heart Transplant; 1989; 8(6):430-43. PubMed ID: 2693662
[TBL] [Abstract][Full Text] [Related]
26. Antiendothelial antibodies after heart transplantation: the accelerating factor in transplant-associated coronary artery disease?
Crisp SJ; Dunn MJ; Rose ML; Barbir M; Yacoub MH
J Heart Lung Transplant; 1994; 13(1 Pt 1):81-91; discussion 91-2. PubMed ID: 7909446
[TBL] [Abstract][Full Text] [Related]
27. The modulation of human aortic endothelial cell ICAM-1 (CD-54) expression by serum containing high titers of anti-HLA antibodies.
Hosenpud JD; Shipley GD; Morris TE; Hefeneider SH; Wagner CR
Transplantation; 1993 Feb; 55(2):405-11. PubMed ID: 7679530
[TBL] [Abstract][Full Text] [Related]
28. The contribution of terminal complement components to acute and hyperacute allograft rejection in the rat.
Brauer RB; Baldwin WM; Ibrahim S; Sanfilippo F
Transplantation; 1995 Jan; 59(2):288-93. PubMed ID: 7839453
[TBL] [Abstract][Full Text] [Related]
29. Acute and hyperacute humoral rejection in kidney allograft recipients treated with anti-human thymocyte antibodies.
Colovai AI; Vasilescu ER; Foca-Rodi A; Kim-Schulze S; Hussaini N; D'agati VD; Markowitz GS; Wang C; Cohen DJ; Hardy MA; Suciu-Foca N
Hum Immunol; 2005 May; 66(5):501-12. PubMed ID: 15935887
[TBL] [Abstract][Full Text] [Related]
30. Vimentin antibodies: a non-HLA antibody as a potential risk factor in renal transplantation.
Carter V; Shenton BK; Jaques B; Turner D; Talbot D; Gupta A; Chapman CE; Matthews CJ; Cavanagh G
Transplant Proc; 2005 Mar; 37(2):654-7. PubMed ID: 15848491
[TBL] [Abstract][Full Text] [Related]
31. Prevention of acute murine cardiac allograft rejection: anti-CD4 or anti-vascular cell adhesion molecule one monoclonal antibodies block acute rejection but permit persistent graft-reactive alloimmunity and chronic tissue remodelling.
Orosz CG; Huang EH; Bergese SD; Sedmak DD; Birmingham DJ; Ohye RG; VanBuskirk AM
J Heart Lung Transplant; 1997 Sep; 16(9):889-904. PubMed ID: 9322138
[TBL] [Abstract][Full Text] [Related]
32. Equal overall rejection rate in pre-transplant flow-cytometric cross-match negative and positive adult recipients in liver transplantation.
Matinlauri IH; Höckerstedt KA; Isoniemi HM
Clin Transplant; 2005 Oct; 19(5):626-31. PubMed ID: 16146554
[TBL] [Abstract][Full Text] [Related]
33. FTY720, an immunosuppressant that alters lymphocyte trafficking, abrogates chronic rejection in combination with cyclosporine A.
Koshiba T; Van Damme B; Rutgeerts O; Waer M; Pirenne J
Transplantation; 2003 Apr; 75(7):945-52. PubMed ID: 12698078
[TBL] [Abstract][Full Text] [Related]
34. Histologic findings proving the existence of humoral rejection in a cardiac allograft.
Abrams J; Amir O; Etheridge WB; Frazier OH
Cardiovasc Pathol; 2007; 16(1):38-42. PubMed ID: 17218213
[TBL] [Abstract][Full Text] [Related]
35. Laboratory-clinical correlates of time-associated lesions in the vascular immunopathology of human cardiac allografts.
Faulk WP; Labarrere CA; Pitts D; Halbrook H
J Heart Lung Transplant; 1993; 12(2):S125-34. PubMed ID: 8476882
[TBL] [Abstract][Full Text] [Related]
36. Vascular endothelial cell HLA-DR antigen and myocyte necrosis in human allograft rejection.
Rabin BS; Griffith BP; Hardesty RL
J Heart Transplant; 1985 May; 4(3):293-5. PubMed ID: 3916499
[TBL] [Abstract][Full Text] [Related]
37. Hyperacute rejection and enhancement of mouse skin grafts by antibodies with a distinct specificity.
Jansen JL; Koene RA; Kamp GJ; Hagemann JF; Wijdeveld PG
J Immunol; 1975 Aug; 115(2):392-4. PubMed ID: 1097512
[TBL] [Abstract][Full Text] [Related]
38. Heart-reactive antibody: a monitor of cardiac rejection.
Ellis RJ; Zabriskie JB
Transplant Proc; 1971 Mar; 3(1):905-7. PubMed ID: 4937990
[No Abstract] [Full Text] [Related]
39. Quantitation of cytomegalovirus infection-associated histologic findings in endomyocardial biopsies of heart allografts.
Koskinen PK; Krogerus LA; Nieminen MS; Mattila SP; Häyry PJ; Lautenschlager IT
J Heart Lung Transplant; 1993; 12(3):343-54. PubMed ID: 8392371
[TBL] [Abstract][Full Text] [Related]
40. Humoral immunity in allograft rejection. The role of cytotoxic alloantibody in hyperacute rejection and enhancement of rat cardiac allografts.
Oluwole SF; Tezuka K; Wasfie T; Stegall MD; Reemtsma K; Hardy MA
Transplantation; 1989 Nov; 48(5):751-5. PubMed ID: 2815247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
